Search

Your search keyword '"Napieczynska, Hanna"' showing total 12 results
Start Over Author "Napieczynska, Hanna" Search Limiters Available in Library Collection
12 results on '"Napieczynska, Hanna"'

1. Mutant Phosphodiesterase 3A Protects From Hypertension-Induced Cardiac Damage

Author

Ercu, Maria, Mücke, Michael B., Pallien, Tamara, Markó, Lajos, Sholokh, Anastasiia, Schächterle, Carolin, Aydin, Atakan, Kidd, Alexa, Walter, Stephan, Esmati, Yasmin, McMurray, Brandon J., Lato, Daniella F., Yumi Sunaga-Franze, Daniele, Dierks, Philip H., Flores, Barbara Isabel Montesinos, Walker-Gray, Ryan, Gong, Maolian, Merticariu, Claudia, Zühlke, Kerstin, Russwurm, Michael, Liu, Tiannan, Batolomaeus, Theda U.P., Pautz, Sabine, Schelenz, Stefanie, Taube, Martin, Napieczynska, Hanna, Heuser, Arnd, Eichhorst, Jenny, Lehmann, Martin, Miller, Duncan C., Diecke, Sebastian, Qadri, Fatimunnisa, Popova, Elena, Langanki, Reika, Movsesian, Matthew A., Herberg, Friedrich W., Forslund, Sofia K., Müller, Dominik N., Borodina, Tatiana, Maass, Philipp G., Bähring, Sylvia, Hübner, Norbert, Bader, Michael, and Klussmann, Enno

Published
2022
Full Text
View/download PDF

2. RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models

Author

Haase, Nadine, Foster, Donald J., Cunningham, Mark W., Bercher, Julia, Nguyen, Tuyen, Shulga-Morskaya, Svetlana, Milstein, Stuart, Shaikh, Sarfraz, Rollins, Jeff, Golic, Michaela, Herse, Florian, Kraker, Kristin, Bendix, Ivo, Serdar, Meray, Napieczynska, Hanna, Heuser, Arnd, Gellhaus, Alexandra, Thiele, Kristin, Wallukat, Gerd, Muller, Dominik N., LaMarca, Babbette, and Dechend, Ralf

Subjects
Alnylam Pharmaceuticals Inc., Maternal mortality -- Models -- Health aspects -- Analysis -- Genetic aspects, Genetic engineering -- Health aspects -- Genetic aspects -- Analysis -- Models, Hypertension -- Genetic aspects, Angiotensins -- Health aspects -- Genetic aspects -- Models -- Analysis, RNA interference -- Models -- Health aspects -- Analysis -- Genetic aspects, Angiotensin II -- Health aspects -- Analysis -- Models, Therapeutics -- Analysis -- Models -- Health aspects, Fetal development -- Models -- Genetic aspects -- Health aspects -- Analysis, Biotechnology industries -- Health aspects -- Analysis -- Genetic aspects -- Models, Pregnancy -- Genetic aspects -- Analysis -- Health aspects -- Models, RNA -- Analysis -- Genetic aspects -- Health aspects -- Models, Health care industry
Abstract

Preeclampsia, with the hallmark features of new-onset hypertension and proteinuria after 20 weeks of gestation, is a major cause of fetal and maternal morbidity and mortality. Studies have demonstrated a role for the renin-angiotensin system (RAS) in its pathogenesis; however, small-molecule RAS blockers are contraindicated because of fetal toxicity. We evaluated whether siRNA targeting maternal hepatic angiotensinogen (Agt) could ameliorate symptoms of preeclampsia without adverse placental or fetal effects in 2 rodent models. The first model used a cross of females expressing human Agt with males expressing human renin, resulting in upregulation of the circulating and uteroplacental RAS. The second model induced ischemia/reperfusion injury and subsequent local and systemic inflammation by surgically reducing placental blood flow mid-gestation (reduced uterine perfusion pressure [RUPP]). These models featured hypertension, proteinuria, and fetal growth restriction, with altered biomarkers. siRNA treatment ameliorated the preeclamptic phenotype in both models, reduced blood pressure, and improved intrauterine growth restriction, with no observed deleterious effects on the fetus. Treatment also improved the angiogenic balance and proteinuria in the transgenic model, and it reduced angiotensin receptor activating antibodies in both. Thus, an RNAi therapeutic targeting Agt ameliorated the clinical sequelae and improved fetal outcomes in 2 rodent models of preeclampsia., Introduction As one of the leading causes of maternal mortality worldwide, hypertensive disorders of pregnancy remain inadequately treated (1). Preeclampsia, a subset of such disorders, occurs in 5% to 8% [...]

Published
2020
Full Text
View/download PDF

3. Phosphodiesterase 3A and Arterial Hypertension

Author

Ercu, Maria, Markó, Lajos, Schächterle, Carolin, Tsvetkov, Dmitry, Cui, Yingqiu, Maghsodi, Sara, Bartolomaeus, Theda U.P., Maass, Philipp G., Zühlke, Kerstin, Gregersen, Nerine, Hübner, Norbert, Hodge, Russell, Mühl, Astrid, Pohl, Bärbel, Illas, Rosana Molé, Geelhaar, Andrea, Walter, Stephan, Napieczynska, Hanna, Schelenz, Stefanie, Taube, Martin, Heuser, Arnd, Anistan, Yoland-Marie, Qadri, Fatimunnisa, Todiras, Mihail, Plehm, Ralph, Popova, Elena, Langanki, Reika, Eichhorst, Jenny, Lehmann, Martin, Wiesner, Burkhard, Russwurm, Michael, Forslund, Sofia K., Kamer, Ilona, Müller, Dominik N., Gollasch, Maik, Aydin, Atakan, Bähring, Sylvia, Bader, Michael, Luft, Friedrich C., and Klussmann, Enno

Published
2020
Full Text
View/download PDF

4. Mouse models of human multiple myeloma subgroups

Author

Winkler, Wiebke, primary, Farré Díaz, Carlota, additional, Blanc, Eric, additional, Napieczynska, Hanna, additional, Langner, Patrick, additional, Werner, Marvin, additional, Walter, Barbara, additional, Wollert-Wulf, Brigitte, additional, Yasuda, Tomoharu, additional, Heuser, Arnd, additional, Beule, Dieter, additional, Mathas, Stephan, additional, Anagnostopoulos, Ioannis, additional, Rosenwald, Andreas, additional, Rajewsky, Klaus, additional, and Janz, Martin, additional

Published
2023
Full Text
View/download PDF

5. Selective endocytosis of Ca 2+ -permeable AMPARs by the Alzheimer’s disease risk factor CALM bidirectionally controls synaptic plasticity

Author

Azarnia Tehran, Domenico, primary, Kochlamazashvili, Gaga, additional, Pampaloni, Niccolò P., additional, Sposini, Silvia, additional, Shergill, Jasmeet Kaur, additional, Lehmann, Martin, additional, Pashkova, Natalya, additional, Schmidt, Claudia, additional, Löwe, Delia, additional, Napieczynska, Hanna, additional, Heuser, Arnd, additional, Plested, Andrew J. R., additional, Perrais, David, additional, Piper, Robert C., additional, Haucke, Volker, additional, and Maritzen, Tanja, additional

Published
2022
Full Text
View/download PDF

8. Imaging neuronal pathways with 52Mn PET:Toxicity evaluation in rats

Author

Napieczynska , Hanna, Severin, Gregory, Fonslet, Jesper, Wiehr, Stefan, Menegakis, Apostolos, Pichler, Bernd J., Calaminus, Carsten, Napieczynska , Hanna, Severin, Gregory, Fonslet, Jesper, Wiehr, Stefan, Menegakis, Apostolos, Pichler, Bernd J., and Calaminus, Carsten

Abstract

Manganese in its divalent state (Mn2+) has features that make it a unique tool for tracing neuronal pathways. It is taken up and transported by neurons in an activity dependent manner and it can cross synapses. It also acts as a contrast agent for magnetic resonance imaging (MRI) enabling visualization of neuronal tracts. However, due to the limited sensitivity of MRI systems relatively high Mn2+ doses are required. This is undesirable, especially in long-term studies, because of the known toxicity of the metal. In order to overcome this limitation, we propose 52Mn as a positron emission tomography (PET) neuronal tract tracer. We used 52Mn for imaging dopaminergic pathways after a unilateral injection into the ventral tegmental area (VTA), as well as the striatonigral pathway after an injection into the dorsal striatum (STR) in rats. Furthermore, we tested potentially noxious effects of the radioactivity dose with a behavioral test and histological staining. 24 h after 52Mn administration, the neuronal tracts were clearly visible in PET images and statistical analysis confirmed the observed distribution of the tracer. We noticed a behavioral impairment in some animals treated with 170 kBq of 52Mn, most likely caused by dysfunction of dopaminergic cells. Moreover, there was a substantial DNA damage in the brain tissue after applying 150 kBq of the tracer. However, all those effects were completely eliminated by reducing the 52Mn dose to 20-30 kBq. Crucially, the reduced dose was still sufficient for PET imaging.

Published
2017

11. Mn-52 as a PET Neural Tract Tracer

Author

Napieczynska , Hanna, Calaminus , Carsten, Severin, Gregory W., Fonslet, Jesper, Pichler, Bernd J., Napieczynska , Hanna, Calaminus , Carsten, Severin, Gregory W., Fonslet, Jesper, and Pichler, Bernd J.

Published
2015

12. Selective endocytosis of Ca2+-permeable AMPARs by the Alzheimer's disease risk factor CALM bidirectionally controls synaptic plasticity.

Author

Tehran, Domenico Azarnia, Kochlamazashvili, Gaga, Pampaloni, Niccolò P., Sposini, Silvia, Shergill, Jasmeet Kaur, Lehmann, Martin, Pashkova, Natalya, Schmidt, Claudia, Löwe, Delia, Napieczynska, Hanna, Heuser, Arnd, Plested, Andrew J. R., Perrais, David, Piper, Robert C., Haucke, Volker, and Maritzen, Tanja

Subjects
*ENDOCYTOSIS, *AMPA receptors, *DISEASE risk factors, *TRANSFERRIN receptors, *NEUROPLASTICITY, *GREEN fluorescent protein, *LIFE sciences, *SNARE proteins
Abstract

The article discusses that according to research, AMPA-type glutamate receptors (AMPARs) mediate fast excitatory neurotransmission, and the plastic modulation of their surface levels determines synaptic strength. The various AMPARs of different subunit compositions plays their roles in synaptic long-term potentiation (LTP) and depression (LTD) to enable learning.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results